Shield
Guardant Health, Inc. · Decision date Jul 26, 2024
What did the FDA approve?
FDA records P230009 as an original PMA application. The recorded decision is approval, dated Jul 26, 2024.
FDA approval order statement
The Shield test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit. Shield is intended for colorectal cancer screening in individuals at average risk of the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Medical Genetics
- Decision date
- Jul 26, 2024
Regulatory record facts
- Identifier
- P230009
- Regulatory pathway
- Premarket approval application
- Applicant
- Guardant Health, Inc.
- Product code
- PHP
- Decision code
- APPR
- Decision date
- Jul 26, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, colorectal neoplasia, DNA methylation and hemoglobin detection.
- Applicant
- Guardant Health, Inc.
- Product code
- PHP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230009 received
Application receipt date recorded by FDA.
P230009 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P230009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ShieldP230009/S020 | Guardant Health, Inc. | PMA supplement | Sep 16, 2026 | FDA |
ShieldP230009/S021 | Guardant Health, Inc. | PMA supplement | Oct 5, 2026 | FDA |
Explore the linked device profile
Other records with product code PHP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SimpleScreen CRCP250029/S003 | Freenome, LLC | PMA supplement | Oct 27, 2026 | FDA |
SimpleScreen CRCP250029 | Freenome, LLC | PMA approval | Jul 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Guardant Health, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3000 Hanover St., Palo Alto, CA, 94304
Sources and methodology
- Original FDA record: P230009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


